HER2陰性乳癌治療薬の世界市場予測および分析...市場調査レポートについてご紹介

【英文タイトル】PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 26
2.1 Catalyst 26
2.2 Related Reports 27
2.3 Upcoming Related Reports 27
3 Disease Overview 28
3.1 Etiology and Pathophysiology 28
3.1.1 Etiology 28
3.1.2 Pathophysiology 29
3.1.3 Basic Breast Anatomy 30
3.2 Disease Classification/Staging Systems 31
3.3 Symptoms 33
3.4 Prognosis 33
3.5 Quality of Life 34
4 Epidemiology 37
4.1 Disease Background 37
4.2 Risk Factors and Comorbidities 37
4.2.1 A family history of breast cancer and BRCA1/2 gene mutations significantly increase the breast cancer risk 39
4.2.2 Reproductive hormonal factors influence the risk of breast cancer 39
4.2.3 Modifiable lifestyle-related factors increase the risk of mortality in breast cancer patients 41
4.2.4 Screening programs have been shown to reduce breast cancer mortality, although the benefits need to be carefully weighed against the risks 43
4.3 Global Trends 46
4.3.1 Incidence 46
4.3.2 Prevalence and Survival 52
4.4 Forecast Methodology 56
4.4.1 Sources Used 58
4.4.2 Sources Not Used 62
4.4.3 Forecast Assumptions and Methods 63
4.5 Epidemiological Forecast for Breast Cancer (2013-2023) – Diagnosed Incident Cases 66
4.5.1 Diagnosed Incident Cases of Breast Cancer 66
4.5.2 Diagnosed Incident Cases of Breast Cancer by Age 68
4.5.3 Diagnosed Incident Cases of Breast Cancer by Menopausal Status 70
4.5.4 Diagnosed Incident Cases of Breast Cancer Segmented by Stage at Diagnosis 72
4.5.5 Age-Standardized Diagnosed Incidence Rate of Breast Cancer 73
4.6 Epidemiological Forecast for Breast Cancer (2013-2023) — Diagnosed Prevalent Cases 74
4.6.1 Five-Year Diagnosed Prevalent Cases of Breast Cancer 74
4.6.2 Five-Year Diagnosed Prevalent Cases by Menopausal Status 76
4.6.3 Five-Year Diagnosed Prevalent Cases by Hormone Receptor Subtypes 77
4.7 Discussion 79
4.7.1 Epidemiological Forecast Insight 79
4.7.2 Limitations of the Analysis 81
4.7.3 Strengths of the Analysis 82
5 Disease Management 84
5.1 Diagnosis and Treatment Overview 84
5.1.1 Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB) 84
5.1.2 Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIC) 86
5.1.3 Treatment Guidelines and Leading Prescribed Drugs 90
5.2 US 91
5.2.1 Diagnosis 91
5.2.2 Clinical Practice 92
5.3 France 95
5.3.1 Diagnosis 95
5.3.2 Clinical Practice 96
5.4 Germany 99
5.4.1 Diagnosis 99
5.4.2 Clinical Practice 100
5.5 Italy 103
5.5.1 Diagnosis 103
5.5.2 Clinical Practice 104
5.6 Spain 106
5.6.1 Diagnosis 106
5.6.2 Clinical Practice 107
5.7 UK 110
5.7.1 Diagnosis 110
5.7.2 Clinical Practice 111
5.8 Japan 114
5.8.1 Diagnosis 114
5.8.2 Clinical Practice 115
5.9 China 117
5.9.1 Diagnosis 117
5.9.2 Clinical Practice 119
6 Competitive Assessment 122
6.1 Overview 122
6.2 Product Profiles (Branded Therapies) 123
6.2.1 Abraxane (nab-paclitaxel) 123
6.2.2 Afinitor (everolimus) 128
6.2.3 Avastin (bevacizumab) 133
6.2.4 Doxil/Caelyx (pegylated liposomal doxorubicin) 137
6.2.5 Halaven (eribulin mesylate) 142
6.2.6 Ixempra (ixabepilone) 145
6.2.7 Xeloda (capecitabine) 148
6.3 Product Profiles (Hormonal Agents) 151
6.3.1 Tamoxifen 151
6.3.2 Faslodex (fulvestrant) 151
6.3.3 Aromatase Inhibitors 152
7 Unmet Need and Opportunity 156
7.1 Overview 156
7.1.1 Defined treatment plan for BRCA mutation-positive patients and prevention of prophylactic surgeries 158
7.1.2 Specific treatment options for TNBC patients 160
7.1.3 Prevention of brain metastasis 161
7.1.4 Neoadjuvant therapy that can downstage tumors 163
7.1.5 For HR+patients, reduced resistance to hormonal agents 164
7.1.6 Improved convenience of administration of hormonal agents 166
8 Pipeline Assessment 168
8.1 Overview 168
8.1.1 Abemaciclib (LY2835219) 169
8.1.2 Buparlisib (BKM- 120) 175
8.1.3 Javlor (vinflunine) 181
8.1.4 LEE011 185
8.1.5 NeuVax (nelipepimut-S/E75) 190
8.1.6 Niraparib (MK4827) 195
8.1.7 NKTR- 102 (etirinotecan pegol) 200
8.1.8 Lynparza (olaparib) 204
8.1.9 Palbociclib (PD-0332991) 209
8.1.10 Talazoparib (BMN 673) 215
8.1.11 Veliparib (ABT-888) 219
8.2 Promising Drugs in Clinical Development 224
8.2.1 PD-/PD-L 1 Immunotherapies 225
9 Current and Future Players 227
9.1 Overview 227
9.2 Trends in Corporate Strategy 229
9.3 Company Profiles 232
9.3.1 AstraZeneca 232
9.3.2 Bristol-Myers Squibb 233
9.3.3 Eli Lilly 235
9.3.4 Pfizer 236
9.3.5 Novartis/GlaxoSmithKline 239
10 Market Outlook 241
10.1 Global Markets 241
10.1.1 Forecast 241
10.1.2 Drivers and Barriers – Global Issues 247
10.2 US 249
10.2.1 Forecast 249
10.2.2 Key Events 252
10.2.3 Drivers and Barriers 253
10.3 France 255
10.3.1 Forecast 255
10.3.2 Key Events 258
10.3.3 Drivers and Barriers 259
10.4 Germany 260
10.4.1 Forecast 260
10.4.2 Key Events 264
10.4.3 Drivers and Barriers 265
10.5 Italy 266
10.5.1 Forecast 266
10.5.2 Key Events 270
10.5.3 Drivers and Barriers 271
10.6 Spain 272
10.6.1 Forecast 272
10.6.2 Key Events 275
10.6.3 Drivers and Barriers 276
10.7 UK 277
10.7.1 Forecast 277
10.7.2 Key Events 281
10.7.3 Drivers and Barriers 282
10.8 Japan 284
10.8.1 Forecast 284
10.8.2 Key Events 287
10.8.3 Drivers and Barriers 288
10.9 China 289
10.9.1 Forecast 289
10.9.2 Key Events 292
10.9.3 Drivers and Barriers 292
11 Appendix 294
11.1 Bibliography 294
11.2 Abbreviations 321
11.3 Methodology 329
11.4 Forecasting Methodology 329
11.4.1 Diagnosed HER2-Negative Breast Cancer Patients 329
11.4.2 Percentage of Drug-Treated Patients 330
11.4.3 Drugs Included in Each Therapeutic Class 330
11.4.4 Launch and Patent Expiry Dates 331
11.4.5 General Pricing Assumptions 332
11.4.6 Individual Drug Assumptions 334
11.4.7 Generic Erosion 342
11.4.8 Pricing of Pipeline Agents 342
11.5 Primary Research – KOLs Interviewed for This Report 353
11.6 Primary Research – High-Prescriber Survey 355
11.7 About the Authors 356
11.7.1 Analyst 356
11.7.2 Director of Oncology 356
11.7.3 Epidemiologist 357
11.7.4 Director of Epidemiology 357
11.7.5 Global Head of Healthcare 358
11.8 About GlobalData 359
11.9 Disclaimer 359


【レポート販売概要】

■ タイトル:HER2陰性乳癌治療薬の世界市場予測および分析
■ 英文:PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023
■ 発行日:2015年1月31日
■ 調査会社:GlobalData
■ 商品コード:GDHC92PIDR
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。